Skip to main content
. 2022 Apr 27;30(8):2709–2721. doi: 10.1016/j.ymthe.2022.04.019

Figure 1.

Figure 1

Identification of human IFNGR1 and mouse Ifngr1 siRNA leads that efficiently modulate IFN-γ signaling

(A) Schematic of siRNA silencing IFN-γ receptor for the modulation of IFN-γ signaling. (B) Human IFNGR1 silencing in HeLa cells, (C) mouse Ifngr1 silencing in N2a cells, and (D) human IFNGR1 silencing in SH-SY5Y cells. Cells were treated with fully modified cholesterol-conjugated siRNAs at 1.5 μM for 72 h. The mRNA levels were measured by using QuantiGene 2.0 assays. siRNA number represents the 5′ position of the mRNA target site. UNT, untreated control. Data are represented as percent of UNT (n = 3, mean ± standard deviation). (E) Dose-response curves of lead siRNA compounds (human 1726, mouse 1641). M, molar concentration of siRNA (n = 3, mean ± standard deviation). (F) Targeting region of lead siRNA in human IFNGR1 and mouse Ifngr1 mRNA.

(G) Human CXCL9/10/11, and (H) Mouse Cxcl9/10/11 mRNA expressions (QuantiGene 2.0 assay) at 6 h post IFN-γ signaling stimulation; cells were treated with siRNA at 1.5 μM for 72 h before IFN-γ stimulation (n = 4, mean ± standard deviation, one-way ANOVA, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001; ns, not significant).